A Strategic Proposal for LaCardio: Establishing Latin America's Premier Theranostics Center

For half a century, LaCardio has stood as a pillar of medical excellence in Colombia and Latin America. This proposal outlines a proven, de-risked pathway to secure that legacy for the next generation by establishing LaCardio as the undisputed leading theranostics center in Latin America. Through the Synapse Latam Management Services Organization (MSO) model, we offer a comprehensive, long-term partnership that delivers complete institutional capability in theranostics, the revolutionary fusion of diagnostics and targeted therapy.

Executive Summary: A Partnership to Secure Generational Leadership

Unrivaled Theranostic Leadership

We will empower LaCardio to build the most advanced clinical theranostics program in Latin America through on-site production of a comprehensive suite of radiopharmaceuticals, including gold-standard cardiac agents like N-13 Ammonia and next-generation theranostic isotopes like Gallium-68 and Copper-64.

Epicenter of Theranostics Research

Our partnership will transform LaCardio into the premier Latin American hub for international clinical trials in theranostics and Radioligand Therapy (RLT), addressing a major bottleneck in the global pharmaceutical industry and creating a significant new revenue stream.

Compelling Financial & Strategic ROI

This proposal outlines a predictable, high-return investment with a rapid payback period. The HIC case study demonstrates that our model mitigates the immense financial risks and delays of conventional projects, ensuring a powerful return that enhances both revenue and institutional prestige.

The efficacy of our model has been decisively proven in Colombia. Our first partner, the Hospital Internacional de Colombia (HIC), will establish a state-of-the-art molecular imaging and theranostics center in just 220 days from contract to first patient dose—years ahead of the 2-4 year schedule typical for conventional installations. This rapid deployment was achieved with a total turnkey investment of $3.4 million, a fraction of the $17.5 million or more required for traditional approaches. By avoiding the multi-year construction delay, HIC averted an estimated $11.6 million in opportunity costs.

The Regional Imperative: Addressing Latency in Latin American Theranostics

Despite LaCardio's established excellence, nuclear medicine and theranostics in Latin America face significant systemic challenges. The region lags considerably behind developed nations in critical infrastructure, specialized expertise, and the widespread adoption of next-generation diagnostic and therapeutic modalities. This deficiency profoundly limits patient access to cutting-edge care, hinders vital medical research, and represents a missed opportunity for scientific growth.

Cyclotron & Production Deficit

Latin America has fewer than 20 medical cyclotrons capable of producing isotopes, compared to over 150 in North America. This stark contrast results in fragile supply chains, limiting access to crucial radiopharmaceuticals like N-13 Ammonia for cardiac imaging and Gallium-68 for prostate cancer, and stifling the development of comprehensive theranostics programs.

Nascent Theranostics Adoption

The integration of advanced molecular imaging with targeted radionuclide therapy, the 'see it, treat it' theranostics paradigm, remains largely undeveloped across the region. Sophisticated procedures that are standard elsewhere are often unavailable, impacting patient outcomes in critical areas like cardiovascular disease and cancer.

Impact on Patient Care & Research

The current deficiencies deny patients access to personalized treatment strategies and participation in global clinical trials. This perpetuates health disparities and limits the potential for improved quality of life. LaCardio's strategic initiative will directly address these gaps, catalyzing regional advancement.

The Clinical Imperative: Leading Latin America's Transition to Theranostics

LaCardio's position as a leader in cardiovascular medicine, transplants, and complex pediatrics is undisputed. In a nation where cardiovascular disease (CVD) remains the leading cause of death, the imperative to adopt more advanced diagnostic and therapeutic tools is both a clinical necessity and a public health mandate. The evolution from anatomical imaging to the "see it, treat it" paradigm of theranostics represents the future of medicine.

The Evolving Role of PET and the Dawn of Theranostics

Current imaging modalities, while valuable, often provide an incomplete picture. The true power of advanced PET imaging lies in its ability to move beyond anatomy and illuminate the underlying biology of disease, providing the diagnostic foundation for targeted radiopharmaceutical therapies.

The Strategic Vulnerability of Dependence

The most significant barrier to becoming a theranostics leader is logistical. Gold-standard radiopharmaceuticals have extremely short half-lives; N-13 Ammonia, for example, has a half-life of just 9.97 minutes. This physical reality makes on-site production an absolute necessity. Relying on external radiopharmacies throttles clinical innovation, prevents participation in cutting-edge research, and creates significant operational inefficiencies.

1

Coronary Artery Disease (CAD)

While SPECT is widely used, PET with Nitrogen-13 (N-13) Ammonia is the undisputed gold standard for assessing myocardial perfusion. It offers superior image quality, lower radiation exposure, and the unique ability to quantify coronary flow reserve (CFR).

2

Cardiac Amyloidosis

This condition is increasingly recognized as a severely underdiagnosed cause of heart failure, present in up to 19% of certain patient groups. The definitive non-invasive diagnosis relies on nuclear scintigraphy.

3

Myocarditis and Inflammatory Cardiomyopathy

Acknowledged as a significant cause of cardiomyopathy and sudden cardiac death, the true prevalence of myocarditis in Colombia is unknown. FDG-PET is a powerful tool for detecting active myocardial inflammation, guiding immunosuppressive therapy, and monitoring treatment response.

The Knowledge Transfer Advantage: A Proven Blueprint for Theranostic Leadership

The decision to establish an in-house radiopharmacy and theranostics program extends far beyond the acquisition of a cyclotron. It is a complex undertaking that requires world-class expertise in facility design, regulatory compliance, radiochemistry, quality assurance, and clinical protocol development. Traditional equipment vendors are structured to sell hardware; their business models are transactional, leaving the hospital to navigate these immense operational and regulatory complexities alone.

NucleoPROJ

Strategic advisors providing comprehensive guidance on business model development, financial planning, and facility design. We lead the regulatory strategy, providing the complete technical dossier and liaison support needed to navigate INVIMA and Ministerio de Minas y Energía requirements.

NucleoLAB & NucleoSITE

Core IONETIX ION-12SC cyclotron and innovative ION Ascend modular shielding solution. This turnkey approach eliminates the need for a massive, multi-year concrete bunker construction project.

NucleoPHARM

Complete, cGMP-compliant radiopharmacy with shielded hot cells, automated synthesis modules, and a fully equipped quality control laboratory. Designed for unparalleled efficiency, dramatically lowering operational costs.

NucleoRAD

Comprehensive radiation safety program, including advanced monitoring systems, personnel contamination monitors, and complete operational and emergency protocols.

NucleoEDU

Comprehensive, multi-stage training and certification program for all key personnel, ensuring the local staff is empowered to run a world-class theranostics facility with excellence and self-sufficiency.

Our Synapse Latam methodology is based on the proven operational success of our U.S. Center of Excellence, CIRA Health. CIRA Health represents the pinnacle of an integrated theranostics ecosystem, combining state-of-the-art clinical service delivery, on-site multi-isotope production, proprietary quantitative imaging software (MyoFlow™), and a robust infrastructure for managing first-in-human clinical trials.

The HIC Case Study: A Colombian Demonstration of Unprecedented ROI

The most compelling evidence for the value and viability of the Synapse Latam partnership model is found in a tangible, documented success story achieved here in Colombia. The transformation of the Hospital Internacional de Colombia (HIC) into a leading theranostics center serves as the ultimate de-risking factor for LaCardio's leadership.

The most striking figure is the $11.6 million in avoided opportunity cost. This was calculated based on the net revenue HIC would have forgone during the minimum 3.5-year construction and implementation gap of a conventional system. This means that the conventional path effectively costs more than three times the total investment in our entire turnkey solution before it generates a single dollar of revenue.

Technological Supremacy: The Engine of Theranostic Leadership

At the heart of our turnkey solution is the IONETIX ION-12SC cyclotron, a technology that represents not an incremental improvement, but a generational leap in radiopharmaceutical production. Born from groundbreaking research at the MIT Plasma Science and Fusion Center, the ION-12SC is the world's first and most advanced commercial compact superconducting cyclotron.

2.3

Tons

System weight of ION-12SC vs. 20+ tons for conventional systems

<34

kW

Power consumption vs. 75-80 kW for conventional systems

65

Days

On-site implementation vs. 1-2+ years for conventional systems

4m×4m

Space

Physical footprint with modular shielding vs. massive concrete bunker

Multi-Isotope Capability: The Key to a Comprehensive Theranostics Program

Fluorine-18 (¹⁸F) FDG

The foundational workhorse of PET imaging, essential for a wide range of oncology, neurology, and cardiology applications.

Nitrogen-13 (¹³N) Ammonia

The gold standard for cardiac perfusion imaging, enabling the most accurate, non-invasive assessment of coronary artery disease.

Gallium-68 (⁶⁸Ga)

A critical isotope for next-generation diagnostics, particularly Gallium-68 PSMA for prostate cancer imaging. This capability is the cornerstone of a modern Cardio-Oncology theranostics program.

Copper-64 (⁶⁴Cu)

The CIRA Health model demonstrates that this on-site production capability is a launchpad for research and development with novel isotopes like Copper-64 for advanced theranostics applications.

A Bespoke Vision: How LaCardio Becomes the Premier Theranostics Center

The true value of this partnership lies not in the hardware we provide, but in the institutional identity it empowers LaCardio to build. By integrating our proven knowledge transfer model and superior technology, LaCardio can synthesize its existing strengths into a new, unparalleled vision of leadership.

Preeminent Clinical Theranostics Center

This partnership will immediately establish LaCardio as home to the "Gold Standard Theranostics Program" in Latin America. The on-site production of N-13 Ammonia, combined with the license to utilize CIRA Health's proprietary MyoFlow™ quantitative analysis software, creates a diagnostic service that is clinically superior and logistically unmatched in the region.

Epicenter of Latin American Theranostics Research

This partnership unlocks a significant new revenue stream by positioning LaCardio as the premier global site in Latin America for radiopharmaceutical clinical trials. The Radioligand Therapy (RLT) market is experiencing explosive growth, with companies like Novartis, Bristol Myers Squibb, and AstraZeneca investing billions.

Hub for Cardio-Oncology and Social Mission

The ability to produce Gallium-68 creates an immediate opportunity for LaCardio to launch a leading Cardio-Oncology program. This project deeply connects with LaCardio's foundational social mission, embodied by the "Give a Life" program, by increasing the accessibility of these critical theranostic treatments.

This model demonstrates that the initial investment is projected to be paid back within the second year of operation, after which the facility becomes a significant and sustainable source of profit for the institution from both clinical and research activities.

Conclusion: The Definitive Choice for Theranostics Leadership

The Conventional Path

  • 2-4 year, high-risk construction project
  • Unpredictable final cost exceeding $17.5 million
  • Significant disruption to hospital operations
  • Multi-million-dollar opportunity cost
  • Immense project management burdens
  • Uncertain operational outcome

The Synapse Latam Partnership

  • Rapid, 220-day implementation timeline
  • Fixed $3.395 million turnkey investment
  • Proven Colombian success story at HIC
  • Comprehensive knowledge transfer model
  • World's most advanced cyclotron technology
  • New high-margin revenue streams

This partnership represents the most direct, effective, and strategically sound means for LaCardio to realize its vision of being the "hospital of the future" and to cement its legacy as the institution that brought the future of personalized medicine to Latin America. We formally request the opportunity to meet with the executive team and the board to discuss the implementation of this strategic framework. Let us begin the journey toward this shared vision of excellence together.